Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 2

Amyotrophic lateral sclerosis: update and new developments

Authors Pratt, Getzoff, Perry J

Received 13 October 2011

Accepted for publication 20 December 2011

Published 24 February 2012 Volume 2012:2 Pages 1—14

DOI https://doi.org/10.2147/DNND.S19803

Review by Single anonymous peer review

Peer reviewer comments 4



Ashley J Pratt1, Elizabeth D Getzoff1, J Jefferson P Perry1,2
1Department of Molecular Biology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; 2The School of Biotechnology, Amrita University, Kollam, Kerala 690525, India

Abstract: Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease. It is typically characterized by adult-onset degeneration of the upper and lower motor neurons, and is usually fatal within a few years of onset. A subset of ALS patients has an inherited form of the disease, and a few of the known mutant genes identified in familial cases have also been found in sporadic forms of ALS. Precisely how the diverse ALS-linked gene products dictate the course of the disease, resulting in compromised voluntary muscular ability, is not entirely known. This review addresses the major advances that are being made in our understanding of the molecular mechanisms giving rise to the disease, which may eventually translate into new treatment options.

Keywords: amyotrophic lateral sclerosis, neurodegeneration, motor neuron disease, genetics, aging

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.